DXCM enters the back half of August with a clear split: short sellers are actively reducing exposure while options traders have quietly moved to their most defensive posture in a year — a tension worth watching as the stock consolidates a 25% monthly gain near $89.
The short side of the ledger is telling a retreat story. Short interest has dropped 8.6% on the week and 15.5% over the past month, now running at 4.1% of the free float — the lowest level in this 30-day window. That decline has come alongside a price that has climbed sharply, suggesting shorts are covering into strength rather than pressing new positions. Borrowing conditions confirm there is no friction driving this: the cost to borrow is a negligible 0.47%, and availability is extraordinarily loose at roughly 1,900% — meaning there are nearly 19 shares available to lend for every one already borrowed. Lender supply is not a constraint here.
Options positioning tells a different story, and the contrast is the most interesting feature of the week. Put demand has jumped sharply: the put/call ratio hit 1.07 on Tuesday, the highest in 52 weeks, running roughly one standard deviation above the 20-day average of 0.98. The shift started around August 11 and has held. That is not the options market of a crowd that just chased a 25% rally with conviction — it reads as hedging by holders who are unsure whether the move has further to run.
The Street, broadly, thinks it does — though not by much at current levels. Following the July 30 earnings beat (the stock jumped 11% the next day and held most of the gain through the week), ten analysts raised price targets in a single session. The bulk landed between $88 and $95, with the consensus mean at $94.12 — barely 5.5% above the $89.16 close. JP Morgan, the most cautious of the active upgrades, held its Neutral rating even while lifting its target from $65 to $82. Bulls anchor on CGM adoption in the non-insulin type 2 diabetes population and the T2NIT coverage expansion; bears point to pricing headwinds and competitive pressure from well-capitalised rivals. The EPS momentum factor score ranks in the 77th percentile on a 30-day basis, and the 30-day PE expansion of roughly 3.5 turns to 30.4x reflects the market pricing in that momentum continuing.
Insider activity adds a note of caution, though context matters. Multiple executives — including Executive Chairman Kevin Sayer, CFO Jereme Sylvain, and President Jake Leach — sold shares over August 20–21, collectively moving several million dollars of stock. Sayer's sales totalled around $2.4 million across three tranches. These are low significance scores (1–2 out of 10), and the pattern looks like routine diversification after a strong price run rather than a directional signal. The 90-day net share figure is marginally positive at roughly 110,000 shares, so the net insider posture is close to flat. UBS Asset Management and Arrowstreet Capital were both adding meaningfully to positions as of the most recent institutional reports, while the three largest holders — BlackRock, Vanguard, and State Street — made only minor adjustments.
Among close peers, TNDM was notably weaker, falling 9% on the week against DXCM's near-flat performance, underscoring that DXCM is outperforming within the diabetes-device complex even as the sector faces shared macro pressures. MDT slipped just over 1% on the week, while ITGR and GEHC were roughly flat to slightly positive.
With the next earnings date set for October 29, the weeks ahead will test whether the post-Q2 momentum can hold at current multiples — and whether the defensive options positioning proves prescient or simply reflects a market reluctant to chase a stock that has already moved 25% in a month.
See the live data behind this article on ORTEX.
Open DXCM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
